Comments on: Novartis Kisqali receives FDA approval for HR+ / HER2- metastatic breast cancer

Comments on: Novartis Kisqali receives FDA approval for HR+ / HER2- metastatic breast cancer /news/newsus-fda-approves-novartiss-kisqali-for-patients-with-hrher2-advanced-or-metastatic-breast-cancer-5762017/ The leading site for news and procurement in the pharmaceutical industry Mon, 13 Mar 2017 18:30:00 +0000 hourly 1 https://wordpress.org/?v=6.6.1